A little more insight to the data would have been helpful, but importantly the trial met its primary endpoints;
To evaluate the pharmacokinetics and systemic bioavailability of single and multiple doses of RECCE327 topical gel applied once daily for 7 days and; To evaluate the safety/tolerability of RECCE®327 topical gel applied once daily for 7 days to normal intact skin in healthy male and female participants.
Importantly progressing/continuing phase III in Australia and Indonesia. No dobt more thorough data analysis insights will follow (but the company should have flagged as much - and fair to criticise that). Clearly positive news however.
A little more insight to the data would have been helpful, but...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.010(3.33%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.0¢ | $25.76K | 82.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13550 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18938 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |